Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta ® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Condition: HER2-positive Breast Cancer Interventions: Drug: TQB2440 injection + Trastuzumab + Docetaxel; Drug: Perjeta + Trastuzumab + Docetaxel Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Conditions: Metastatic Prostate Cancer; Hormone Sensitive Prostate Cancer; Chemotherapy Effect Interventions: Drug: Docetaxel; Drug: Rezvilutamide Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
